ACOG Alpha Cognition Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1655923 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-48.6%
TTM EPS YoY8.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin99.8%
Operating margin-149.6%
Net margin-147.3%
FCF margin-152.7%
EBITDA margin-148.2%
Returns
ROE-74.2%
ROA-53.9%
ROIC (approx.)-696.4%
Asset turnover0.37x
Leverage & solvency
Liabilities / assets22.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.22M | — |
| Cost of revenue | $603,400 | — |
| Gross profit | $9.62M | — |
| R&D expense | $1.87M | $3.92M |
| SG&A expense | $29.08M | $8.01M |
| Operating income | -$22.66M | -$12.01M |
| Interest expense | — | $105,273 |
| Pretax income | -$9.34M | -$621,897 |
| Net income | -$20.67M | -$14.79M |
| EBITDA | -$22.60M | -$11.93M |
| EPS (basic) | -1.17 | -2.04 |
| EPS (diluted) | -1.18 | -2.04 |
| Weighted avg. shares (diluted) | 17.68M | 7.25M |
| Banking | ||
| Provision for credit losses | — | $55,000 |
| Balance sheet | ||
| Cash & equivalents | $66.05M | $48.56M |
| Receivables | $4.24M | — |
| Inventory | $5.12M | $615,133 |
| Current assets | $79.01M | $50.25M |
| PP&E, net | $328,540 | $27,077 |
| Intangibles | $391,423 | $412,969 |
| Total assets | $79.73M | $50.74M |
| Current liabilities | $9.13M | $3.35M |
| Total liabilities | $17.20M | $11.64M |
| Shareholders' equity | $62.53M | $39.09M |
| Shares outstanding | 21.74M | 16.02M |
| Cash flow statement | ||
| Operating cash flow | -$20.38M | -$7.76M |
| Capital expenditure | $293,489 | $26,701 |
| Free cash flow | -$20.67M | -$7.78M |
| Investing cash flow | -$293,489 | -$26,701 |
| Financing cash flow | $38.21M | $54.85M |
| Depreciation & amortization | $58,572 | $81,220 |
| Stock-based compensation | $4.92M | $1.13M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.